A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
GSK961081 has previously been administered to healthy subjects in a nebulised formulation and
the first part of this study which will be conducted in healthy subjects proposes to bridge
the change from nebulised to DPI formulation of GSK961081 before administration to patients.
The second part of the study will be conducted in COPD patients and aims to assess the safety
and bronchodilator profile of GSK961081 over 24 hours, during 14 days dosing.